Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 15, 2009

Femta Signs On Lonza to Manufacture Preclinical RA Candidate

  • Femta Pharmaceuticals signed a manufacturing services and license agreement with Lonza for its lead humanized interleukin 6 mAb called FM101. Femta says that it aims to submit an IND for the rheumatoid arthritis candidate in 2010.

    The license deal gives Femta access to Lonza’s GS (glutamine synthetase) Gene Expression System™ as well as cell-line, purification, and process-development expertise to support cGMP process development for the clinical program.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »